Pulmonary Hypertension News Forums › Forums › Research and Development › Roivant seeks to reduce time, cost of PAH drug development

  • Research & Development

    Roivant seeks to reduce time, cost of PAH drug development

    Posted by Pulmonary Hypertension News Moderator on July 6, 2018 at 7:49 am

    Roivant recently announced the launch of two new business units, Roivant Pharma and Roivant Health, as well as the creation of Altavant Sciences, a company that will focus on developing new therapies, including RVT-1201 as a potential treatment for pulmonary arterial hypertension (PAH).

    Roivant is also looking to decrease the time and cost of drug development. Click here to read more.

    Roivant has undergone a staff reorganization that included a 10 percent reduction in its workforce to support lower costs. Do you agree with this approach?

    replied 5 years, 10 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .